NKTR-255

Nektar Therapeutics' NKTR-255, an IL-15 agonist, significantly improved complete response rates (CRR) in lymphoma patients after CAR-T therapy.

Bicistronic CD19/CD22-directed CAR T-cell therapy (B019) demonstrates safety and high remission rates in children with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).

The follicular lymphoma treatment landscape is evolving, with over 55 therapies in development by more than 50 active pharmaceutical companies.

NKTR-255, combined with durvalumab, demonstrates potential in treating radiation-induced lymphopenia in locally advanced NSCLC patients undergoing chemoradiation.

Nektar's NKTR-255, combined with durvalumab, significantly improved lymphocyte recovery in NSCLC patients after chemoradiation, compared to historical controls.